|
The recall of Vioxx affects millions of current and former Vioxx users. These current and former Vioxx users are sure to have many questions relating to Vioxx and where to get help. The following Vioxx questions and answers are here to help you sort through the Vioxx questions you may have and if you are a current or former Vioxx user, will help you decide if you have a possible Vioxx claim that you should speak with a Vioxx attorney about.
1. What action did Merck take regarding Vioxx?
Merck announced a voluntary worldwide withdrawal of Vioxx (rofecoxib).
2. What is Vioxx?
Vioxx is a COX-2 selective nonsteroidal anti-inflammatory drug (NSAID). Vioxx is also related to the nonselective NSAIDs, such as ibuprofen and naproxen. Vioxx is a prescription medicine used to relieve signs and symptoms of arthritis, acute pain in adults, and painful menstrual cycles.
3. Did the FDA require this action?
No, Merck made this decision independent of input from the FDA. The FDA has not had an opportunity to review the data from the study that was stopped in the depth that Merck has, but agrees with the company that there appear to be significant safety concerns for patients, particularly those taking the drug chronically.
4. What action did the FDA take?
FDA issued a public health advisory concerning the use of Vioxx. This advisory is based on Merck & Co., Inc. voluntarily withdrawing Vioxx from the market due to safety concerns.
5. What should I do if I am currently taking Vioxx?
We encourage people taking Vioxx to contact their physician to discuss discontinuing use of Vioxx and alternative treatments. Any decision about which drug product to take to treat your symptoms should be made in consultation with your physician based on an assessment of your specific treatment needs. We also advise you to contact us IMMEDIATELY so that we can review your legal rights.
6. What are the likely long-term health effects, if any, of taking this product?
The new study shows that Vioxx causes an increased risk in cardiovascular events such as heart attack and strokes during chronic use.
7. What evidence supports the health risk?
Merck's decision to withdraw Vioxx from the market is based on new data from a trial called the APPROVe [Adenomatous Polyp Prevention on VIOXX] trial. In the APPROVe trial, Vioxx was compared to placebo (sugar-pill). The purpose of the trial was to see if Vioxx 25 mg was effective in preventing the recurrence of colon polyps. This trial was stopped early because there was an increased risk for serious cardiovascular events, such as heart attacks and strokes, first observed after 18 months of continuous treatment with Vioxx compared with placebo.
8. Why wasn't the APPROVe trial stopped earlier?
The APPROVe trial began enrollment in 2000. The trial was being monitored by an independent data safety monitoring board (DSMB). It was not stopped earlier because the results for the first 18 months of the trial allegedly did not show any increased risk of confirmed cardiovascular events on Vioxx.
9. What did FDA know about the risk of heart attack and stroke when it approved Vioxx?
FDA originally approved Vioxx in May 1999. The original safety database included approximately 5000 patients on Vioxx and allegedly did not show an increased risk of heart attack or stroke. A later study, VIGOR (VIOXX GI Outcomes Research), was primarily designed to look at the effects of Vioxx on side effects such as stomach ulcers and bleeding and was submitted to the FDA in June 2000. The study showed that patients taking Vioxx had fewer stomach ulcers and bleeding than patients taking naproxen, another NSAID, however, the study also showed a greater number of heart attacks in patients taking Vioxx. The VIGOR study was discussed at a February 2001 Arthritis Advisory Committee and the new safety information from this study was added to the labeling for Vioxx in April 2002. Merck then began to conduct longer-term trials to obtain more data on the risk for heart attack and stroke with chronic use of Vioxx.
10. Was Vioxx reviewed by the FDA before being put on the market?
Vioxx received only a six-month expedited review because the drug potentially provided a therapeutic advantage over existing approved drugs due to fewer gastrointestinal side effects, including bleeding.
11. What other drugs are similar to Vioxx?
Vioxx is a COX-2 selective, nonsteroidal anti-inflammatory drug (NSAID). Other COX-2 selective NSAIDs on the market at this time are Celebrex (celecoxib) and Bextra (valdecoxib). Vioxx is also related to the nonselective NSAIDs, such as ibuprofen and naproxen. You should consult your physician to determine which treatment is right for you.
12. Does today's action suggest that other drugs in the same class are dangerous?
The results of clinical studies with one drug in a given class may indicate risks associated with other drugs in the same class. All of the NSAIDs have risks when taken chronically, especially of gastrointestinal (stomach) bleeding, but also liver and kidney toxicity. Patients using these drugs for a long period of time (longer than two weeks) should be under the care of a physician.
13. Will Vioxx be recalled?
The FDA did not request a recall of Vioxx, however this product is being voluntarily withdrawn from the market by Merck.
14. Can my pharmacist continue to fill my prescription for Vioxx?
No, Merck is initiating a market withdrawal in the United States to the pharmacy level. This means Vioxx will no longer be available at pharmacies.
15. Where can I get more information?
You can obtain more information from Merck at:
If, after reading the Vioxx questions and answers you wish to gain more Vioxx information, or you feel you have a Vioxx claim that you want to speak with a Vioxx attorney about, call 877-VIOXX-SUIT. 877-VIOXX-SUIT offers a free Vioxx consultation with an experienced Vioxx attorney who can help you with your Vioxx claim. |
